Modified release formulations of memantine oral dosage forms

CAFC
  • US 8,039,009 B2
  • Filed: 06/16/2005
  • Issued: 10/18/2011
  • Est. Priority Date: 06/17/2004
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating Alzheimer'"'"'s disease comprising once daily administration of a modified release solid oral dosage form comprising 28 mg ±

  • 5% of memantine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymeric carrier substantially contributing to the modification of the release of the memantine or pharmaceutically acceptable salt thereof, said dosage form sustaining release of the memantine or pharmaceutically acceptable salt thereof from about 4 hours to about 24 hours following entry of said form into a use environment, wherein said dosage form has a single phase dissolution rate of less than about 80% after passage of about 6 hours following said entry into said use environment.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×